The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.

Journal of Clinical Pharmacology
Nithya SrinivasNaresh Punwani

Abstract

Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft-versus-host disease. The objective of this study was to assess pharmacokinetics and safety of 300-mg itacitinib dosed in participants with normal renal function (n = 10), severe renal impairment (n = 8), and end-stage renal disease (ESRD) on hemodialysis (n = 8). Serial plasma and urine samples (urine from normal and severe groups only) were collected before dosing until 72 hours after dosing. In the ESRD group, itacitinib was evaluated in 2 periods, when dosed before (period 1) and after (period 2) a hemodialysis session. Geometric mean ratios (90% confidence interval) in participants with severe renal impairment, ESRD period 1 and ESRD period 2 relative to participants with normal renal function were 1.65 (1.13-2.39), 0.71 (0.49-1.03), and 0.83 (0.57-1.20) for maximum plasma drug concentration and 2.23 (1.56-3.18), 0.81 (0.57-1.16), and 0.95 (0.66-1.35) for area under the plasma concentration-time curve from time zero to infinity. Itacitinib was well tolerated, and 3 grade 1 treatment-emergent adverse events were reported over the course of the study. Given the magnitude of exposure changes in participants with severe renal impair...Continue Reading

References

Aug 1, 1993·British Journal of Anaesthesia·A C ElstonG R Park
Jan 22, 2003·Seminars in Dialysis·Albert W Dreisbach, Juan J L Lertora
Aug 9, 2005·Pharmacology & Therapeutics·Hong SunLeslie Z Benet
Aug 11, 2006·Journal of the American Society of Nephrology : JASN·Thomas D NolinJonathan Himmelfarb
Apr 5, 2008·Clinical Pharmacology and Therapeutics·T D NolinV Pichette
Dec 17, 2008·Hematology·Stephanie J Lee, Mary E D Flowers
Apr 9, 2009·Pediatric Blood & Cancer·Volkan HazarAkif Yesilipek
Sep 25, 2009·Clinical Pharmacology and Therapeutics·A W Dreisbach
Dec 15, 2010·Seminars in Nephrology·Eric P CohenJohn E Moulder
Aug 21, 2013·Current Oncology Reports·John Magenau, Daniel R Couriel
May 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinCorey S Cutler
Jan 1, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mark A SchroederJohn F DiPersio
Jul 10, 2019·Journal of Clinical Pharmacology·April M BarbourSwamy Yeleswaram

❮ Previous
Next ❯

Citations

Oct 2, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eduardo HuartePaul A Smith
Jan 13, 2021·Journal of Clinical Pharmacology·April M BarbourNaresh Punwani

❮ Previous
Next ❯

Methods Mentioned

BETA
equilibrium dialysis

Software Mentioned

SAS Enterprise Guide

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.